Benitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual Meeting
Benitec Biopharma announced that interim Phase 1b/2a clinical results for high dose and low dose BB-301 have been accepted for oral presentation at the ASGCT Annual Meeting. The data set includes 12-month follow-up for four Cohort 1 completers, 24-month results for the first Cohort 1 patient, and interim results for the first Cohort 2 patient, demonstrating continued durable improvements.
Key figures
- Drug Name
- BB-301
- Phase Of Trial
- Phase 1b/2a
- Opmd patient prevalence
- 15000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.